ES2003064A4 - Metodos de diagnostico para detectar linfomas en el hombre. - Google Patents

Metodos de diagnostico para detectar linfomas en el hombre.

Info

Publication number
ES2003064A4
ES2003064A4 ES87305863T ES87305863T ES2003064A4 ES 2003064 A4 ES2003064 A4 ES 2003064A4 ES 87305863 T ES87305863 T ES 87305863T ES 87305863 T ES87305863 T ES 87305863T ES 2003064 A4 ES2003064 A4 ES 2003064A4
Authority
ES
Spain
Prior art keywords
detect
lymphomas
man
diagnostic methods
chromosomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES87305863T
Other languages
English (en)
Other versions
ES2003064T3 (es
Inventor
Carlos M Croce
Yoshihide Tsujimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wistar Institute of Anatomy and Biology
Original Assignee
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Institute of Anatomy and Biology filed Critical Wistar Institute of Anatomy and Biology
Publication of ES2003064A4 publication Critical patent/ES2003064A4/es
Application granted granted Critical
Publication of ES2003064T3 publication Critical patent/ES2003064T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA SECUENCIA DE LAS REGIONES DE CODIFICACION DE PROTEINAS DEL GEN BCL-2 ESTA PROVISTAS AL IGUAL QUE CLONES DE BACTERIAS QUE PRODUCEN LAS PROTEINAS. SE HAN HECHO INTENTOS PARA DETECTAR UNA CLASE DE CELULA-B NEOPLASMAS ASOCIADOS CON UNA RECOLOCACION DE CROMOSOMAS ENTRE LOS CROMOSOMAS 14 Y 18. ESTA RECOLECCION ESTA PRESENTE EN LA MAYORIA DE LOS CASOS DE LINFOSOMAS FOLICULARES DE PERSONAS. UN INTENTO EMPLEA UN ANTICUERPO QUE ES INMUNOREACTIVO CON UNA PROTEINA HUMANA QUE ESTA SOBRECOMPRIMIDA DEBIDO A UNA RECOLECCION DE CROMOSOMAS. OTRO INTENTO INCLUYE LA MEDIDA DE LA CANTIDAD DE MRNA QUE HIBRIDIZA UN GEN PROXIMO PARA RECOLOCAR UN PUNTO DE RUPTURA.
ES87305863T 1986-07-09 1987-07-02 Metodos de diagnostico para detectar linfomas en el hombre. Expired - Lifetime ES2003064T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/883,687 US5015568A (en) 1986-07-09 1986-07-09 Diagnostic methods for detecting lymphomas in humans

Publications (2)

Publication Number Publication Date
ES2003064A4 true ES2003064A4 (es) 1988-10-16
ES2003064T3 ES2003064T3 (es) 1994-09-01

Family

ID=25383120

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87305863T Expired - Lifetime ES2003064T3 (es) 1986-07-09 1987-07-02 Metodos de diagnostico para detectar linfomas en el hombre.

Country Status (9)

Country Link
US (5) US5015568A (es)
EP (1) EP0252685B1 (es)
JP (1) JPS63100379A (es)
AT (1) ATE90792T1 (es)
AU (1) AU602704B2 (es)
CA (1) CA1340827C (es)
DE (2) DE3786200T2 (es)
ES (1) ES2003064T3 (es)
GR (1) GR880300131T1 (es)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US6841541B1 (en) 1992-02-21 2005-01-11 The Trustees Of The University Of Pennsylvania Regulation of BCL-2-gene expression
AU5932790A (en) * 1989-07-03 1991-01-17 Temple University Tcl-5 gene rearrangement involved in t-cell leukemia and melanoma
EP0507868A4 (en) * 1989-12-27 1992-11-04 Us Commerce Diagnostic probe for detecting human stomach cancer
WO1991013172A1 (en) * 1990-02-23 1991-09-05 The Board Of Trustees Of The Leland Stanford Junior University Transcription factors having a pathogenetic role in human neoplasias
IT1255770B (it) * 1992-05-22 1995-11-15 Consiglio Nazionale Ricerche Oligonucleotidi antisenso ad attivita' antitumorale, composizioni farmaceutiche che li comprendono, e loro impieghi
WO1993025683A1 (en) 1992-06-12 1993-12-23 Massachusetts Institute Of Technology A gene which prevents programmed cell death
US6902732B2 (en) 1992-06-12 2005-06-07 Massachusetts Institute Of Technology Identification and characterization of a gene which protects cells from programmed cell death and uses therefor
US5501952A (en) * 1992-07-17 1996-03-26 Aprogenex, Inc. Analogues of reporter groups as background reducers in hybridization assays
US5641672A (en) * 1993-06-09 1997-06-24 The Trustees Of Columbia University In The City Of New York Cloning and uses of the genetic locus bcl-6
US5646008A (en) * 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
US5622852A (en) * 1994-10-31 1997-04-22 Washington University Bcl-x/Bcl-2 associated cell death regulator
US6696548B2 (en) 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
US5529925A (en) 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US5672686A (en) * 1994-08-09 1997-09-30 Immunogen, Inc. Bcl-Y - specific antibodies
US7175995B1 (en) 1994-10-27 2007-02-13 Thomas Jefferson University TCL-1 protein and related methods
US5985598A (en) * 1994-10-27 1999-11-16 Thomas Jefferson University TCL-1 gene and protein and related methods and compositions
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5695944A (en) * 1995-05-05 1997-12-09 Thomas Jefferson University Modulation of bcl-2 phosphorylation
US6221615B1 (en) 1995-05-12 2001-04-24 Apoptosis Technology, Inc. Peptides and compositions which modulate apoptosis
US5656725A (en) * 1995-05-12 1997-08-12 Apoptosis Technology, Inc. Peptides and compositions which modulate apoptosis
US5789201A (en) * 1996-02-23 1998-08-04 Cocensys, Inc. Genes coding for bcl-y a bcl-2 homologue
AU728863B2 (en) * 1996-03-27 2001-01-18 Walter And Eliza Hall Institute Of Medical Research, The A novel mammalian gene, bcl-w, belongs to the bcl-2 family of apoptosis-controlling genes
AUPN896596A0 (en) * 1996-03-27 1996-04-26 Walter And Eliza Hall Institute Of Medical Research, The Therapeutic molecules
US5821082A (en) 1996-05-23 1998-10-13 St. Louis University Health Sciences Center Anti-proliferation domain of a human Bcl-2 and DNA encoding the same
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US5837838A (en) 1997-03-14 1998-11-17 The Burnham Institute Bax inhibitor proteins
US6337184B1 (en) 1997-04-01 2002-01-08 Jeffrey B. Miller Molecular marker for muscle stem cells
EP0878552A1 (en) * 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Molecular detection of chromosome aberrations
US6849400B1 (en) 1997-07-23 2005-02-01 Gen-Probe Incorporated Methods for detecting and measuring spliced nucleic acids
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US20010041342A1 (en) * 1998-04-01 2001-11-15 The General Hospital Corporation, A Massachusetts Corporation Molecular marker for muscle stem cells
JP2002513587A (ja) * 1998-05-04 2002-05-14 ダコ エー エス 染色体異常を検出するための方法およびプローブ
EP1247093B1 (en) * 2000-01-14 2005-03-23 MIGENIX Corp. Screening assays using intramitochondrial calcium
AU2001231009A1 (en) * 2000-01-21 2001-07-31 Beth Israel Deaconess Medical Center Use of pro-apoptotic factors in treatment of atherosclerosis
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US20030044803A1 (en) * 2000-09-22 2003-03-06 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of JAK1
US20020164576A1 (en) * 2000-09-22 2002-11-07 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2
US20040147473A1 (en) * 2000-11-10 2004-07-29 Warrell Raymond P. Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US20070098728A1 (en) * 2001-09-24 2007-05-03 Pedersen Finn S Novel compositions and methods in cancer
ES2374311T3 (es) * 2002-03-13 2012-02-15 Genomic Health, Inc. Obtención de perfil de expresión génica en tejidos tumorales biopsiados.
WO2004046386A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
AU2004211955B2 (en) * 2003-02-06 2009-05-14 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
WO2004074518A1 (en) * 2003-02-20 2004-09-02 Genomic Health, Inc. Use of intronic rna to measure gene expression
AU2004248120B2 (en) * 2003-05-28 2009-04-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
AU2004248140A1 (en) * 2003-05-30 2004-12-23 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
HUE050365T2 (hu) 2003-06-24 2022-09-28 Genomic Health Inc Rákkiújulás valószínûségének elõrejelzése
AU2004258085B2 (en) * 2003-07-10 2010-05-27 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
AU2004309396B2 (en) 2003-12-23 2010-05-13 Genomic Health, Inc. Universal amplification of fragmented RNA
ES2636470T3 (es) * 2004-04-09 2017-10-05 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
EP1789581A4 (en) * 2004-07-12 2008-06-11 Sbarro Health Res Organization METHOD FOR DETERMINING THE PRESENCE OF CANCER BY ANALYSIS OF THE EXPRESSION OF CDK9 AND / OR CYCLIN T1 IN LYMPHOID TISSUE
WO2006041835A2 (en) * 2004-10-04 2006-04-20 University Of Washington Methods of inhibiting cell death or inflammation in a mammal
JP4939425B2 (ja) 2004-11-05 2012-05-23 ジェノミック ヘルス， インコーポレイテッド 乳癌の治療反応の予後および予測の分子指標
CA2585571C (en) * 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
CN103820562B (zh) * 2005-08-01 2015-05-13 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
JP2009507918A (ja) * 2005-09-12 2009-02-26 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション Ｂｃｌ２関連癌の診断及び療法のための組成物及び方法
US20090270484A1 (en) * 2005-10-05 2009-10-29 The Ohio State University Research Foundation WWOX Vectors and Uses in Treatment of Cancer
EP1969147B1 (en) 2006-01-05 2014-07-30 The Ohio State University Research Foundation microRNA-based methods for the diagnosis of stomach cancer
ES2553442T3 (es) 2006-01-05 2015-12-09 The Ohio State University Research Foundation Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón
US7670840B2 (en) 2006-01-05 2010-03-02 The Ohio State University Research Foundation Micro-RNA expression abnormalities of pancreatic, endocrine and acinar tumors
SG169395A1 (en) * 2006-02-09 2011-03-30 Univ South Florida Detection of cancer by elevated levels of bcl-2
EP2369011A1 (en) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Microrna fingerprints during human megakaryocytopoiesis
EP2041317A4 (en) * 2006-07-13 2009-10-14 Univ Ohio State Res Found METHODS AND COMPOSITIONS BASED ON MICRO-RNA FOR THE DIAGNOSIS AND TREATMENT OF COLON CANCER RELATED DISEASES
EP2061907B1 (en) * 2006-09-19 2011-11-23 The Ohio State University Research Foundation Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181
US8252538B2 (en) 2006-11-01 2012-08-28 The Ohio State University MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma
WO2008094545A2 (en) * 2007-01-31 2008-08-07 The Ohio State University Research Foundation Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
AU2008248319B2 (en) * 2007-04-30 2013-09-05 The Ohio State University Research Foundation Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis
ES2537349T3 (es) * 2007-06-08 2015-06-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Métodos para determinar un subtipo de carcinoma hepatocelular
CN101918424A (zh) 2007-06-15 2010-12-15 俄亥俄州立大学研究基金会 用于靶向由Drosha介导的微小RNA加工的致癌ALL-1融合蛋白
CN101809169B (zh) * 2007-07-31 2013-07-17 俄亥俄州立大学研究基金会 通过靶向dnmt3a和dnmt3b恢复甲基化的方法
EP2653561B1 (en) * 2007-08-03 2016-03-02 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
EP3028708A1 (en) * 2007-08-22 2016-06-08 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
EP2775001B1 (en) * 2007-09-06 2016-03-09 The Ohio State University Research Foundation MicroRNA signatures in human ovarian cancer
EP2212440A4 (en) * 2007-10-11 2011-04-06 Univ Ohio State Res Found METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF ADENOCARCINOMES OF DISHES
CA2703707A1 (en) 2007-10-26 2009-04-30 The Ohio State University Research Foundation Methods for identifying fragile histidine triad (fhit) interaction and uses thereof
CN101918594A (zh) * 2007-11-30 2010-12-15 俄亥俄州立大学研究基金会 肺癌中外周血中的微rna表达特征谱和靶向
CN102027129B (zh) * 2008-02-28 2014-03-12 俄亥俄州立大学研究基金会 用于前列腺相关病症的诊断、预后和治疗的基于微rna的方法和组合物
CA2717026A1 (en) * 2008-02-28 2009-09-03 The Ohio State University Research Foundation Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof
EP2307028B1 (en) 2008-06-11 2013-10-02 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
US9569912B2 (en) 2008-06-26 2017-02-14 Shopatm Bv (Sarl) Article storage and retrieval apparatus and vending machine
AU2010321555B2 (en) 2009-11-23 2015-10-15 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
ES2606146T3 (es) 2010-11-12 2017-03-22 The Ohio State University Research Foundation Métodos relacionados con microARN-21 y reparación de desapareamiento en cáncer colorrectal
CN103313706A (zh) 2010-11-15 2013-09-18 俄亥俄州立大学研究基金会 控制释放粘膜粘合系统
US8664192B2 (en) 2011-03-07 2014-03-04 The Ohio State University Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer
EP2766500A4 (en) 2011-10-14 2015-10-14 Univ Ohio State METHOD AND MATERIALS IN CONNECTION WITH EGG CANCER
AU2012352265B2 (en) 2011-12-13 2017-02-16 Ohio State Innovation Foundation Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis
US8859202B2 (en) 2012-01-20 2014-10-14 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755086A (en) * 1971-02-09 1973-08-28 Hoffmann La Roche Diagnostic method utilizing synthetic deoxyrilionucleotide oligomer template
US4535058A (en) * 1982-10-01 1985-08-13 Massachusetts Institute Of Technology Characterization of oncogenes and assays based thereon
US4661586A (en) * 1981-11-17 1987-04-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies
US4582788A (en) * 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4513088A (en) * 1983-03-30 1985-04-23 The Board Of Trustees Of The Leland Stanford Junior University Assay for monoclonal antibody against surface Ig of a human B cell tumor
US4798787A (en) * 1984-09-19 1989-01-17 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
US4679918A (en) * 1984-10-23 1987-07-14 Ace Ronald S Ophthalmic glass/plastic laminated lens having photochromic characteristics and assembly thereof
US4701409A (en) * 1984-11-15 1987-10-20 The Wistar Institute Detection of B-cell neoplasms
US4692405A (en) * 1985-03-05 1987-09-08 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies to antigen on activated human B-cells and assay therefor, protein antigenic determinant therefor and method of making same
AU615876B2 (en) * 1985-08-21 1991-10-17 Oncogene Science, Inc. Immunoassay for the detection of Oncogene encoded products
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
IT1244983B (it) * 1991-04-29 1994-09-13 Raggio Italgene Spa Procedimento per rivelare sequenze di acidi nucleici e kit per la sua utilizzazione.

Also Published As

Publication number Publication date
DE3786200D1 (de) 1993-07-22
AU7532887A (en) 1988-02-18
US5523393A (en) 1996-06-04
GR880300131T1 (en) 1988-12-16
ES2003064T3 (es) 1994-09-01
JPS63100379A (ja) 1988-05-02
US5015568A (en) 1991-05-14
AU602704B2 (en) 1990-10-25
CA1340827C (en) 1999-11-23
US5459251A (en) 1995-10-17
US5506344A (en) 1996-04-09
ATE90792T1 (de) 1993-07-15
EP0252685A2 (en) 1988-01-13
US5595869A (en) 1997-01-21
EP0252685A3 (en) 1990-07-11
EP0252685B1 (en) 1993-06-16
DE252685T1 (de) 1988-06-30
DE3786200T2 (de) 1993-10-07

Similar Documents

Publication Publication Date Title
ES2003064A4 (es) Metodos de diagnostico para detectar linfomas en el hombre.
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
ES2043607T3 (es) Agentes fibrinoliticos modificados.
MX9102042A (es) Reactivo para la prueba de tiempo de la protrombina con base en el factor de tejido.
ES2179077T3 (es) Acido glutamico decarboxilasa clonada.
DE69033032D1 (de) Integriertes zellkultur-proteinreinigungssystem zur automatisierten herstellung und reinigung von zellkulturprodukten
IT7948725A0 (it) Perfezionamento nei profilattici erelativo procedimento di produzione
FI963884A0 (fi) Diagnoosi, hoito ja solu- ja eläinmallit tauteja varten, joihin liittyy mitokondriodefektejä
FI864760L (fi) Ihmiskehoon istutettava keinotekoinen rauhanen
ES2011798B3 (es) Mejoras en la fabricacion de vidrio curvado.
ES2038969T3 (es) Procedimiento para la renaturalizacion de proteinas.
ES2059436T3 (es) Proteina de la membrana exterior f de pseudomonas aeruginosa.
ES2057004T3 (es) N-alcoxialquilamidas de hidroxiacidos y composiciones a base de las mismas para el tratamiento de la piel.
IT1201760B (it) Procedimento ed impianto per la realizzazione di calzature con suola in gomma vulcanizzata ed intersuola in poliuretano bicomponente
FI893681A0 (fi) N-2,3-butadienyltri- och tetra-aminoalkanderivat.
ES544664A0 (es) Procedimiento para el diagnostico in vitro del sexo
IT1203782B (it) Impiego in terapeutica degli agonisti dopaminergici
IT8449279A1 (it) Cuoio in crosta vellutato sintetico e procedimento per la sua produzione
ES2043596T3 (es) Feniloxazolonas cardiotonicas.
ES469908A1 (es) Procedimiento de utilizacion de salinomicina.
Kagan et al. Individuality and objective and subjective reality
FR2565375B1 (fr) Cadran indiquant le cycle de l'energie des organes, des meridiens de l'acupuncture, des fonctions et des elements dans les 24 heures et dans les saisons en accord avec la loi des cinq elements chinois
ES551053A0 (es) Perfeccionamientos en el metodo de tratamiento de simil-cuero y cuero
DE3650590D1 (de) Verwendung von Tergurid zur Herstellung eines Arzneimittels zur Behandlung geriatrischer Beschwerden
IT1207053B (it) Dispositivo di controllo e di intercettazione dell'acqua di carica del le vasche di lavastoviglie e simili

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 252685

Country of ref document: ES